SCHEMBL3562453

SCHEMBL3562453

Cc1cc(-c2ccc(Cl)cc2)nc(-c2ccnc(-c3ccc(S(=O)(=O)NC(C)(C)C)s3)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.41
KDM1A O60341 4/20 0.35
MAOA P21397 4/20 0.35
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
MAP4K4 O95819 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
PRNP P04156 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
DRD2 P14416 1/20 0.34
HTR2C P28335 1/20 0.34
DRD3 P35462 1/20 0.34
HTR6 P50406 1/20 0.34
CNKSR1 Q969H4 1/20 0.34
ADAMTS5 Q9UNA0 2/20 0.34
MMP1 P03956 1/20 0.34
MMP14 P50281 1/20 0.34
ADAM17 P78536 1/20 0.34
PFKFB3 Q16875 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559064 0.91 ABL1 (0.39) GABRA1MAPTKDM4EPKMPRNP
SCHEMBL3569669 0.89 HSP90AA1 (0.39) GABRA1MAPTTP53KDM4EPKM
SCHEMBL3559682 0.89 KDM4E (0.40) GABRA1KDM1AMAPTTP53KDM4E
SCHEMBL3556174 0.88 PFKFB4 (0.41) GABRA1KDM1AMAOAMAPTTP53
SCHEMBL2403917 0.85 RXFP1 (0.35) KDM4EPKMRXFP1ALOX5APFEN1
SCHEMBL3570689 0.85 CA12 (0.41) GABRA1MAPTMAP4K4RAB9AL3MBTL1
SCHEMBL3568411 0.81 KDM1A (0.42) KDM1AMAOAMAPTMAP4K4KDM4E
SCHEMBL3556405 0.80 PTGS2 (0.36) GABRA1MAPTTP53PRNPRXFP1
SCHEMBL3563428 0.80 KDM4E (0.45) MAPTTP53KDM4ERXFP1RAB9A
SCHEMBL3559279 0.80 GSK3B (0.38) KDM1AKDM4ERXFP1RAB9AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 GABRA1 108/4885KDM1A 2672/4885MAOA 673/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 GABRA1 135/4885KDM1A 1773/4885MAOA 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.